MMJ Recs

DECEMBER 28, 2023

Image by Budding on Unsplash CBD for Epilepsy: Insights into Its Anticonvulsant Properties Epilepsy is a neurological disorder characterized by recurrent seizures, and for some patients, conventional treatments may be inadequate.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Veriheal

APRIL 11, 2022

I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “I look forward to a time when they are not considered alternative therapies or home remedies but actually first-line therapies,” said the CEO of Zelira, Oludare Odumosu. “We

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

DECEMBER 1, 2021

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-?), Unlike other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-? a driver of chronic inflammation. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona Institute ‘s psilocybin therapy for major depressive disorder. Then, something strange happened.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

NOVEMBER 16, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “For

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 25, 2021

Epilepsy Treatment. This study is, of course, well-vetted, and has offered plenty of hope to sufferers of epilepsy. Therapy is definitely an important route to take, but one reason why CBD products have become so popular as of late is that they help people to better cope with these mental health issues.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-? Unlike other anti-TNF-?

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Cannabis Law Report

NOVEMBER 23, 2021

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-?), Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? a driver of chronic inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Radiation therapy works well for some patients. Portugal subsidises medical cannabis.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Radiation therapy works well for some patients. Portugal subsidises medical cannabis.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

The Joint Blog

JANUARY 12, 2020

A small clinical trial at Colorado State University published in the Journal of the American Veterinary Medical Association in June found CBD oil reduced seizure frequency in 89 percent of the epileptic dogs that received it. Bookout said his organization has recorded very few health incidents involving CBD and no deaths.

Pets 36

Pets CBD Clinical Trials Research and Development 36

The Joint Blog

APRIL 22, 2022

Treats Epilepsy. Furthermore, the FDA recognizes the benefits of CBD oil and has approved many branded oils to treat some forms of epilepsy. But, if it is consumed along with the right amount of therapy, it might work wonders for PTSD patients. In many cases, CBD can prove beneficial in treating epileptic seizures.

Oil 26

Oil CBD Topical Clinical Trials 26

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

The Joint Blog

FEBRUARY 24, 2021

Numerous trials have been run using medical marijuana and CBD tinctures to treat or reduce the symptoms of Parkinson’s Disease. This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s?

Treatment 55

Treatment Clinical Trials Collective Patients 55

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

CannaMD

AUGUST 8, 2020

Designed to treat seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome , Epidiolex is a purified (> 98% oil-based) CBD extract administered via oral spray. Prior to receiving FDA approval, Epidiolex underwent a number of clinical trials establishing the medical efficacy of CBD.

CBD 100

CBD DEA Research and Development Hemp 100

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Further, Eleusis’s subsidiary Andala plans to solve the practical, “last mile” challenges of interventional psychiatric therapy.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. Corine de Boer, M.D.,

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. Food and Drug Administration’s review. “We Mack, Chairman and CEO of Virpax.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

CannaTech

SEPTEMBER 23, 2019

NICE develop evidence-based guidelines on a wide range of health-related topics, including integrating novel and emerging therapies. Last week NICE released the first draft of their evidence-based guidelines, concluding it could not recommend CBMPs for routine use because of high cost and a dearth of clinical trial evidence.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. Hypothermia is typically the go-to therapy for treating newborn infants after a stroke. Ancient therapies.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

DECEMBER 21, 2019

ASD is a worldwide problem that needs to be kept in check, and although currently there is no cure to the problem so many breakthroughs have been recorded via a couple of therapy procedures amongst which is the use of CBD. The major points critics bring up regarding this subject include: Uncertainties of the long term effects of the therapy.

Research and Development 59

Research and Development CBD Conditions Therapy 59

Green Relief

MAY 12, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. Hypothermia is typically the go-to therapy for treating newborn infants after a stroke. Ancient therapies.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Refractory paediatric epilepsy. Conclusions. Palliative care indications. Cancer pain. Neuropathic pain. Spasticity from neurological conditions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. Success rates of up to 80% have been observed for CBD related autism therapy. Beyond alternative therapies, education and medication are the two most accepted ways of treating autism.

Treatment 76

Treatment Oil CBD Therapy 76